The latest news from ANEUVO
The latest news from Anuevo
ANEUVO Launches US Study of ExaStim, a Non-invasive Spinal Neuromodulation System to Evaluate its Safety and Effectiveness for Paralysis due to Spinal Cord Injury
The ASPIRE clinical study is designed to demonstrate the safety and efficacy of the ExaStim® TSS system using non-invasive spinal cord stimulation to improve/regain the motor function of individuals with SCI. A maximum of 140 patients will be enrolled at up to 14 sites in the U.S.
ANEUVO is a Contributing Partner of NASCIC
NASCIC brings together like-minded organizations, individuals, and groups to improve research, care, cure, and policies impacting people living with spinal cord injury, their families, and the community.
Innovation in Spinal Cord Neuromodulation: Functional Improvements with Transcutaneous Spinal Stimulation for SCI
May 18 | 12:25 – 1:25 PM
Loews Hotel, New OrleansPresenters:
Dimitry Sayenko, M.D., Ph.D. Houston Methodist
Monica Perez, PT, Ph.D. Shirley Ryan AbilityLab
ANEUVO CEO Yi-Kai Lo to Present at Unite 2 Fight for Paralysis
The symposium is “a collaborative gathering that prioritizes the voice of the Spinal Cord Injury (SCI) Community, bringing together research scientists, clinicians, and community advocates, along with investors and industry leaders to exchange information and strategies for achieving recovery from SCI.” The event takes place Thursday, October 21, through Saturday, October 23, 2021.
ANEUVO Awarded $999,999 from the National Science Foundation
ANEUVO* today announced that it has been recently awarded a National Science Foundation (NSF) Small Business Innovation Research (SBIR) grant for $999,999 to conduct research and development work on an ingestible bioelectronic capsule for closed-loop diagnosis and treatment of gastrointestinal (GI) disorders. With this grant, ANEUVO will advance its novel GI technology development toward pre-clinical validation.
We are now ANEUVO.
Niche Biomedical is rebranding in preparation for continued growth and success! The name reflects new approaches to treatment, neural technology, and neural therapies and sets us apart as we begin moving toward future clinical trials and, ultimately, commercialization. We appreciate your support, encouragement, and attention since the formation of Niche Biomedical in 2016. We look forward to bringing innovative and effective medical solutions to help patients in need.